COMMUNIQUÉ DE PRESSE publié le 12/08/2025 à 07:00, il y a 8 mois 21 jours VALNEVA : Rapport Semestriel 2025
COMMUNIQUÉ DE PRESSE publié le 12/08/2025 à 07:00, il y a 8 mois 21 jours Focus on sustainable profitability: Komax Group reduces costs considerably Komax Group achieves sustainable profitability by reducing costs considerably amid market challenges. Positive EBIT and cost savings of CHF 25 million confirmed in 2025 half-year results Market Challenges EBIT Cost Reduction Komax Group Sustainable Profitability
COMMUNIQUÉ DE PRESSE publié le 12/08/2025 à 07:00, il y a 8 mois 21 jours Sonova expands Infinio range and enters new market segment with Phonak’s smallest and first rechargeable in-the-ear hearing aid Sonova expands Infinio range with Phonak's smallest rechargeable in-the-ear hearing aid, Phonak Virto R Infinio. The launch marks an important step in entering the market segment Sonova Hearing Aid Phonak Infinio Rechargeable
COMMUNIQUÉ DE PRESSE publié le 12/08/2025 à 07:00, il y a 8 mois 21 jours LLB successfully concludes share repurchase programme Liechtensteinische Landesbank AG successfully concludes share repurchase programme holding 1.4% of share capital Share Repurchase Capital Structure Liechtensteinische Landesbank LLB Treasury Management
COMMUNIQUÉ DE PRESSE publié le 12/08/2025 à 07:00, il y a 8 mois 21 jours SCHOTT Pharma delivers solid final third-quarter results SCHOTT Pharma reports solid Q3 2025 results with 1% revenue growth, 32.4% EBITDA margin, and strategic innovations Revenue Growth EBITDA Margin SCHOTT Pharma Innovations Q3 2025 Results
COMMUNIQUÉ DE PRESSE publié le 12/08/2025 à 07:00, il y a 8 mois 21 jours Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS) Newron Pharmaceuticals initiates Phase III ENIGMA-TRS program with evenamide as add-on therapy for treatment-resistant schizophrenia patients, targeting TRS population Newron Pharmaceuticals Evenamide Phase III Treatment-resistant Schizophrenia ENIGMA-TRS Program
COMMUNIQUÉ DE PRESSE publié le 12/08/2025 à 07:00, il y a 8 mois 21 jours Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates Valneva SE reports €97.6 million revenues in H1 2025, confirms 2025 financial outlook. Highlights financial results, R&D progress, and commercial updates Revenues Financial Results Valneva SE R&D Progress 2025 Outlook Commercial Updates
COMMUNIQUÉ DE PRESSE publié le 12/08/2025 à 07:00, il y a 8 mois 21 jours Valneva publie ses résultats financiers du premier semestre 2025 et fait un point sur ses activités Valneva publie ses résultats financiers du premier semestre 2025 et fait un point sur ses activités. Chiffre d’affaires en hausse, trésorerie solide et perspectives confirmées. Détails disponibles sur le site de la société Résultats Financiers Perspectives Valneva Vaccins Premier Semestre 2025
COMMUNIQUÉ DE PRESSE publié le 12/08/2025 à 06:55, il y a 8 mois 21 jours PolyPeptide delivers +24% growth in H1 2025, successful ramp-up at its Belgian site, 2025 full-year guidance revised towards the upper end of the range PolyPeptide Group reports +24% revenue growth in H1 2025, revises full-year guidance towards upper range. EBITDA improved to EUR 4.4 million, major investments in capacity expansion projects EBITDA Revenue Growth Capacity Expansion PolyPeptide Group Full-year Guidance
COMMUNIQUÉ DE PRESSE publié le 12/08/2025 à 06:55, il y a 8 mois 21 jours TAG Immobilien AG reports strong growth in FFO I and EPRA NTA in the first half of 2025; positive valuation results in Germany and Poland; further decline in LTV TAG Immobilien AG reports strong growth in FFO I and EPRA NTA in the first half of 2025; positive valuation results in Germany and Poland; further decline in LTV TAG Immobilien AG EPRA NTA LTV FFO I Valuation Results
Publié le 30/04/2026 à 21:21, il y a 1 jour 22 heures CP -Mise à disposition du rapport financier annuel 2025
Publié le 30/04/2026 à 20:00, il y a 1 jour 23 heures AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Publié le 30/04/2026 à 20:00, il y a 1 jour 23 heures AMA Corp PLC : Résultats 2025 & Chiffre d'affaires du 1er trimestre 2026
Publié le 02/05/2026 à 01:30, il y a 18 heures 15 minutes Uraniumx Reports Strong Financial Position Ahead of Spring Drill Program
Publié le 02/05/2026 à 00:50, il y a 18 heures 55 minutes CoTec Announces Annual Stock Option, Restricted Share Unit And Deferred Share Unit Grants
Publié le 02/05/2026 à 00:00, il y a 19 heures 45 minutes Redwood AI Announces Enhanced AI Models, Increasing Evaluated Chemical Reactions Following Preliminary Results from UBC Collaboration
Publié le 02/05/2026 à 00:00, il y a 19 heures 45 minutes Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies
Publié le 01/05/2026 à 22:30, il y a 21 heures 15 minutes Nextech3D.ai Appoints New Independent Auditor
Publié le 02/05/2026 à 15:35, il y a 4 heures 10 minutes Ecuador's banana sector renews labor agreement, with jobs meeting global standards
Publié le 01/05/2026 à 17:45, il y a 1 jour 2 heures Burkhalter Group acquires Progressio Holding GmbH and anplaq ag, Tamins (GR)